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MaOBJECTIVES The purpose of this study was to determine the efﬁcacy and safety of radial versus femoral access
in women undergoing coronary angiography/intervention.
BACKGROUND The risk of bleeding and vascular access site complications are higher in women than in men.
METHODS In a pre-speciﬁed RIVAL (RadIal Vs femorAL access for coronary intervention) subgroup analysis, we
compared outcomes in women (n ¼ 1,861) and men (n ¼ 5,160) randomized to radial versus femoral access.
RESULTS Overall, women were at higher risk of major vascular complications compared with men (4.7% vs. 1.7%;
p < 0.0001). Major vascular complications were signiﬁcantly reduced with radial access in women (3.1% vs. 6.1%; hazard
ratio [HR]: 0.5; 95% conﬁdence interval [CI]: 0.32 to 0.78; p ¼ 0.002) and in men (0.7% vs. 2.8%; HR: 0.27; 95% CI:
0.17 to 0.45; p < 0.0001; interaction p ¼ 0.092). Crossover rates were higher with radial compared with femoral access
in women (11.1% vs. 1.9%; HR: 5.88; p < 0.0001) and men (6.3% vs. 1.9%; HR: 3.32; p < 0.0001; interaction p ¼ 0.054).
Percutaneous coronary intervention (PCI) success rates were similar irrespective of access site (women: HR: 1.05;
p ¼ 0.471; men: HR: 1.00; p ¼ 0.888; interaction p ¼ 0.674), with no differences in PCI complications. In multivariable
analyses, female sex was an independent predictor of major vascular complications (HR: 2.39; 95% CI: 1.76 to 3.25;
p < 0.0001). There were consistent ﬁndings for women and men, with no difference for the primary composite endpoint
of death, myocardial infarction, stroke, and non–coronary artery bypass grafting bleeding (women: 3.9% vs. 5.0%;
HR: 0.77; 95% CI: 0.50 to 1.19; men: 3.54% vs. 3.5%; HR: 1.00; 95% CI: 0.75 to 1.34; interaction p ¼ 0.325).
CONCLUSIONS Women undergoing coronary angiography and PCI have a higher risk of vascular access site compli-
cations compared with men, and radial access is an effective method to reduce these complications. (J Am Coll Cardiol
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ABBR EV I A T I ON S
AND ACRONYMS
CABG = coronary artery
bypass grafting
CI = conﬁdence interval
GP = glycoprotein
HR = hazard ratio
NNT = number needed to treat
PCI = percutaneous coronary
intervention
STEMI = ST-segment elevation
myocardial infarction
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506O ver the past 5 years, there has beenan increase in the uptake of radialaccess for percutaneous coronary
intervention (PCI) for both elective and emer-
gency cases in Europe and North America
(1–3). The RIVAL (RadIal Vs femorAL access
for coronary intervention) trial randomized
7,021 patients with acute coronary syndrome
to either radial or femoral access for coronary
angiography and PCI and showed that, over-
all, there was no difference in the primary
composite outcome of death, myocardial
infarction (MI), stroke, or non–coronary ar-tery bypass graft (CABG) bleeding, with a signiﬁcant
reduction in major vascular complications (4).
Observational data suggest that female sex is an
independent risk factor for major bleeding and that
the use of radial access for PCI likely reduces this risk
(5,6). However, there are concerns that radial access
may be technically more challenging in women due to
smaller radial arteries and increased rates of radial
artery spasm, potentially leading to lower procedural
success rates. Most randomized trials comparing
radial with femoral access have enrolled more men
than women, making data regarding radial access
speciﬁc to women very pertinent (7).SEE PAGE 513We sought to determine the efﬁcacy and safety of
radial versus femoral access in women and men in
this pre-speciﬁed subgroup analysis.
METHODS
RIVAL was a randomized, parallel-group, multicenter
trial. Patients with acute coronary syndromes, with
or without ST-segment elevation, and planned for
invasive therapy were included. Patients with car-
diogenic shock, severe peripheral arterial disease
precluding femoral approach, previous coronary
bypass surgery with use of more than 1 internal
mammary artery, and a negative Allen’s test (absence
of dual circulation of hand) were ineligible for inclu-
sion. The study was approved by all appropriate
national regulatory authorities and ethics commit-
tees of participating centers, and participants pro-
vided written informed consent prior to enrollment.
The trial was coordinated by the Population Health
Research Institute at McMaster University and Ham-
ilton Health Sciences in Hamilton, Ontario, Canada.
Details of RIVAL’s study design are published else-
where (4,8).
The primary efﬁcacy outcome was a composite
of death, MI, stroke, or non-CABG major bleedingat 30 days. Other outcomes included composite of
death, MI, or stroke; components of primary out-
come; major vascular complications; access site pain;
crossover rates; PCI success and complication rates;
procedure duration; contrast volumes used; and
patient preference for next procedure.
Major vascular complications included retroperi-
toneal hematoma, pseudoaneurysm requiring ultra-
sound compression, thrombin injection or surgical
repair, large hematomas requiring prolonged hospi-
talization, arteriovenous ﬁstulae, limb ischemia or
damage to adjacent nerve, and other surgical access
site repair. RIVAL major bleeding was deﬁned as
bleeding that was fatal; resulted in transfusion
of $2 U red blood cells; caused signiﬁcant hypoten-
sion requiring inotropes; required surgical interven-
tion; caused severe disabling sequelae; was
intracranial or intraocular; or led to a drop in
hemoglobin of at least 50 g/l. ACUITY (Acute Cathe-
terization and Urgent Intervention strategy) non–
CABG-related major bleeding was deﬁned as RIVAL
major bleeding, large hematomas, and pseudoaneur-
ysms requiring intervention (4).
STATISTICAL ANALYSES. The ﬁnal intention-to-treat
analyses included all patients, irrespective of
whether they crossed over to another access site
or did not undergo PCI. A signiﬁcance level of 0.05
with 2-sided test was used, and all analyses were
performed using SAS version 9.2 (SAS Institute, Cary,
North Carolina).
Women versus men was 1 of 6 pre-speciﬁed, pre-
randomization subgroups. The efﬁcacy and safety of
radial versus femoral access for the primary and sec-
ondary outcomes in women versus men were
assessed by comparison of survival curves (estimated
with the Kaplan-Meier method) for the 2 approaches
by log-rank statistic. The interaction p value was then
calculated to estimate any signiﬁcant differences be-
tween women and men. Centers were included as
random effects in the COX model to account for any
intercenter variability. Demographic, baseline ther-
apy, clinical, investigatory, and procedural charac-
teristics of the 2 comparison groups were compared
using chi-square and Wilcoxon rank sum tests as
appropriate.
A multivariable analysis using the Cox proportional
hazard model was performed to determine whether
women versus men was independently associated
with increased risk of major vascular complications
after adjusting for sex, age, bodymass index, diabetes,
arterial sheath size, use of a closure device, whether
PCI was performed, glycoprotein (GP) IIb/IIIa inhi-
bitor use, ST-segment elevation myocardial infarction
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507(STEMI) versus non-STEMI, and peripheral arterial
disease. A similar multivariable analysis was also
performed to determine predictors of access site
crossover after adjusting for sex, age, radial center
volume, body mass index, height, diabetes, whether
PCI was performed, STEMI versus non-STEMI, and
previous CABG.
RESULTS
A total of 7,021 patients from 158 hospitals in
32 countries were originally enrolled in the RIVAL
trial (June 6, 2006, to November 2, 2010). A total ofTABLE 1 Baseline Characteristics, Invasive Procedures After Random
Women (n ¼ 1,861
Radial
(n ¼ 908)
Demographics
Age, yrs 65.7 (11.2)
Age >75 yrs 215 (23.7)
Diagnosis
UA 285 (31.4)
NSTEMI 430 (47.4)
STEMI 193 (21.3)
Past history
Current smoker 165 (18.2)
Hypertension 615 (67.7)
Diabetes 228 (25.1)
Prior MI 103 (11.3)
Prior PCI 103 (11.3)
Prior CABG 20 (2.2)
PAD 22 (2.4)
Elevated biomarker at presentation 433/715 (60.6) 457
Antithrombotic therapy in hospital
Aspirin 893 (98.3)
Clopidogrel 862 (94.9)
LMWH 478 (52.6)
IV UFH 281 (30.9)
Bivalirudin 17 (1.9)
GP IIb/IIIa inhibitors 174 (19.2)
Invasive procedures
Coronary angiography 907 (99.9)
PCI 529 (58.3)
Stent 491/529 (92.8) 543
BMS 318/491 (64.8) 382
DES 189/491 (38.5) 186
CABG 64 (7.0)
Procedural characteristics
Arterial sheath size
#5-F 169/907 (18.6) 89
6-F 679/907 (74.9) 751
$7-F 7/907 (0.8) 38
Age values are mean  SD. Other values are n (%) or n/N (%).
BMS ¼ bare-metal stent(s); CABG ¼ coronary artery bypass graft; DES¼ drug-eluting s
MI ¼ myocardial infarction; NSTEMI ¼ non–ST-segment elevation myocardial infarcti
STEMI ¼ ST-segment elevation myocardial infarction; UA ¼ unstable angina; UFH ¼ unf1,861 women (908 radial; 953 femoral) and 5,160 men
(2,599 radial; 2,561 femoral) were included in the
subgroup analyses. Table 1 shows baseline charac-
teristics and procedural characteristics of the study
population. It illustrates that both female and male
subgroups allocated to radial versus femoral access
were well matched in terms of demographics, back-
ground medical history, and type of acute coronary
syndrome presentation. However, GP IIb/IIIa inhibi-
tor usage was greater in the male subgroup. In terms
of procedural differences, 5-F catheters were used
more frequently with radial access (women 18.6%;
men 12.9%) than femoral access (women 9.3%; menization, and Procedural Characteristics
) Men (n ¼ 5,160)
Femoral
(n ¼ 953)
Radial
(n ¼ 2,599)
Femoral
(n ¼ 2,561)
65.1 (11.4) 60.5 (11.4) 60.4 (11.6)
219 (23.0) 291 (11.2) 310 (12.1)
285 (29.9) 713 (27.4) 620 (24.2)
451 (47.3) 1,124 (43.2) 1,155 (45.1)
217 (22.8) 762 (29.3) 786 (30.7)
179 (18.8) 918 (35.3) 918 (35.8)
640 (67.2) 1,503 (57.8) 1,436 (56.1)
244 (25.6) 553 (21.3) 478 (18.7)
122 (12.8) 521 (20.0) 500 (19.5)
121 (12.7) 328 (12.6) 287 (11.2)
9 (0.9) 59 (2.3) 66 (2.6)
18 (1.9) 69 (2.7) 64 (2.5)
/736 (62.1) 1,153/1,837 (62.8) 1,156/1,775 (65.1)
940 (98.6) 2,586 (99.5) 2,549 (99.5)
894 (93.8) 2,506 (96.4) 2,464 (96.2)
483 (50.70) 1,328 (51.1) 1,336 (52.2)
285 (29.9) 887 (34.1) 825 (32.2)
27 (2.8) 59 (2.3) 82 (3.2)
178 (18.7) 713 (27.4) 666 (26.0)
951 (99.8) 2,592 (99.7) 2,555 (99.8)
577 (60.5) 1,782 (68.6) 1,772 (69.2)
/577 (94.1) 1,696/1,782 (95.2) 1,690/1,772 (95.4)
/543 (70.3) 1,110/1,696 (65.4) 1,162/1,690 (68.8)
/543 (34.3) 646/1,696 (38.1) 586/1,690 (34.7)
54 (5.7) 244 (9.4) 237 (9.3)
/951 (9.4) 336/2,592 (13.0) 148/2,555 (5.8)
/951 (79.0) 2,029/2,592 (78.3) 2,060/2,555 (80.6)
/951 (4.0) 28/2,592 (1.1) 174/2,555 (6.8)
tent(s); GP ¼ glycoprotein; LMWH ¼ low-molecular-weight heparin; IV ¼ intravenous;
on; PAD ¼ peripheral arterial disease; PCI ¼ percutaneous coronary intervention;
ractionated heparin.
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5085.7%), and catheters size $7-F were used more
frequently with femoral access (women 3.9%; men
6.8%) than radial access (women 0.7%; men 1.0%).
The rate of drug-eluting stent usage was similar for
the 2 groups.
EFFICACY OUTCOMES. Findings for women and men
were consistent, with no difference for the primary
composite outcome of death, MI, stroke, or non-CABG
bleeding at 30 days between radial and femoral accessTABLE 2 Outcomes for Radial Versus Femoral Access in Women and
Radial Femoral
Primary outcome*
Women 36/908 (3.9) 48/953 (5.0)
Men 92/2,599 (3.5) 91/2,561 (3.5)
Secondary outcomes: death, MI, or stroke
Women 29/908 (3.1) 38/953 (3.9)
Men 83/2,599 (2.9) 76/2,561 (2.9)
RIVAL non-CABG major bleeding
Women 10/908 (1.1) 15/953 (1.5)
Men 14/2,599 (0.5) 18/2,561 (0.7)
ACUITY non-CABG bleeding
Women 34/908 (3.7) 67/953 (7.0)
Men 32/2,599 (1.2) 86/2,561 (3.3)
Major vascular complications
Women 29/908 (3.1) 59/953 (6.1)
Men 20/2,599 (0.7) 72/2,561 (2.8)
PCI complications†
Women 18/529 (3.4) 27/577 (4.6)
Men 53/1,782 (2.9) 60/1,772 (3.3)
Coronary dissection with reduced ﬂow during PCI
Women 13/529 (2.4) 9/577 (1.5)
Men 17/1,782 (0.9) 16/1,772 (0.9)
Persistent pain at access site for $2 weeks
Women 37/877 (4.2) 37/925 (4.0)
Men 50/2,501 (2.0) 67/2,467 (2.7)
Patient prefers radial access next procedure
Women 737/856 (86.1) 443/884 (50.1)
Men 2,226/2,427 (91.7) 1,186/2,326 (51.0)
Crossover rates
Women 101/908 (11.1) 19/953 (1.9)
Men 164/2,599 (6.3) 51/2,561 (1.9)
PCI success
Women 506/529 (95.8) 551/557 (95.5
Men 1,698/1,782 (95.3) 1,684/1,772 (95.3
Procedural duration, min
Women 37.6  24.4, 31.0 (20.0–50.0) 38.5  24.0, 34.5 (23.0
Men 40.2  24.7, 35.0 (23.0–52.0) 39.2  24.3, 34.0 (22.0
Fluoroscopy time, min
Women 12.7  38.3 10.1  18.7
Men 12.9  16.7 10.7  10.9
Values are n/N (%), mean  SD, or median (quartile 1–quartile 3). *Primary efﬁcacy ou
coronary dissection with reduced ﬂow, abrupt closure, no reﬂow, coronary perforation,
ACUITY ¼ Acute Catheterization and Urgent Intervention strategy; CI ¼ conﬁdence in(women: radial 3.9% vs. femoral 5.0%; hazard ratio
[HR]: 0.77; 95% conﬁdence interval [CI]: 0.50 to 1.19;
men: 3.5% vs. 3.5%; HR: 1.00; 95% CI: 0.75 to 1.34;
p for interaction ¼ 0.325) (Table 2). In the female
subgroup, there was no signiﬁcant difference be-
tween radial and femoral access and no difference,
when compared with men, for the secondary out-
comes of composite death, MI, stroke (p ¼ 0.377; p for
interaction ¼ 0.298), and non-CABG major bleeding
(p ¼ 0.323; p for interaction ¼ 0.748).Men
HR 95% CI p Value Interaction p Value
0.77 0.50–1.19 0.247
1.00 0.75–1.34 0.995 0.325
0.80 0.50–1.30 0.377
1.08 0.79–1.47 0.629 0.298
0.67 0.30–1.49 0.323
0.77 0.38–1.56 0.471 0.748
0.5 0.33–0.76 0.001
0.36 0.24–0.55 <0.0001 0.327
0.5 0.32–0.78 0.002
0.27 0.17–0.45 <0.0001 0.092
0.74 0.40–1.35 0.326
0.88 0.61–1.27 0.495 0.626
1.58 0.68–3.70 0.289
1.07 0.54–2.12 0.852 0.471
0.8149
0.095
<0.0001
<0.0001
5.88 3.60–9.61 <0.0001
3.32 2.43–4.55 <0.0001 0.054
) 1.05 0.93–1.18 0.471
) 1.00 0.94–1.08 0.888 0.674
–50.0) 0.5406
–50.00) 0.2484
0.1046
<0.0001
tcome: composite of death, MI, stroke, or non-CABG bleeding. †PCI complications:
and stent thrombosis (deﬁnite and probable).
terval; HR ¼ hazard ratio; other abbreviations as in Table 1.
FIGURE 1 Rates of Major Vascular Complications of Radial
Versus Femoral Access in Both Women and Men
The interaction p was nonsigniﬁcant (0.07). The absolute risk
reduction (ARR) for radial access versus femoral access in women
was 3.0%, compared with 2.0% in men. NNT ¼ number needed
to treat.
FIGURE 2 Major Reasons for Access Site Crossover From
Radial to Femoral in Women and Men
There was a signiﬁcant difference in the rates of crossover due to
radial artery spasm (9.5% vs. 3.3%; p < 0.001) and radial artery
loops (2.5% vs. 0.8%; p ¼ 0.006) in women versus men.
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509Major vascular complications were signiﬁcantly
reduced with the use of radial access in women (3.1%
vs. 6.1%; HR: 0.50; 95% CI: 0.32 to 0.78; p ¼ 0.002),
and men (0.7% vs. 2.8%; HR: 0.27; 95% CI: 0.17 to
0.45; p < 0.0001; p for interaction ¼ 0.092) (Table 2).
In terms of absolute beneﬁt for major vascular com-
plications, among women, the absolute risk reduction
for radial versus femoral was 3.0% (number needed
to treat [NNT] ¼ 33) and for men was 2.0% (NNT ¼ 49;
p for interaction ¼ 0.07) (Figure 1).
There was a signiﬁcant reduction in bleeding rate,
as deﬁned by ACUITY criteria, for both women (3.7%
vs. 7.0%; HR: 0.50; 95% CI: 0.33 to 0.76; p ¼ 0.001)
and men (radial 1.2%; femoral 3.3%, HR: 0.36; 95%
CI: 0.24 to 0.55; p < 0.0001) with no interaction
between groups (p for interaction ¼ 0.327).
Crossover rates from radial to femoral access were
higher than femoral to radial in both groups (women:
11.1% vs. 1.9%; HR: 5.88; 95% CI: 3.60 to 9.61; p <
0.0001; men: 6.3% vs. 1.9%; HR: 3.32; 95% CI: 2.43 to
4.55; p < 0.001; p for interaction ¼ 0.054). The rea-
sons for access site crossover were collected in 3,190
of 7,021 patients enrolled in the RIVAL trial. In
women, radial-to-femoral crossover occurred in 101 of
908 cases (11.1%). Of the cases that had documented
reasons for crossover (3,190 of 7,021), the most com-
mon reasons were radial artery spasm (women: 9.5%
vs. men: 3.3%; p < 0.001), radial artery loop (women:
2.5% vs. men: 0.78%; p ¼ 0.006), and subclavian
tortuosity (women: 2.5% vs. men: 1.7%; p ¼ 0.33)
(Figure 2).PCI was completed successfully with equal efﬁcacy
in women and men irrespective of access site (women:
95.8% vs. 95.5%; HR: 1.05; 95% CI: 0.93 to 1.18;
p¼0.471; men: 95.3% vs. 95.3%; HR: 1.00; 95% CI: 0.94
to 1.08; p ¼ 0.888; p for interaction ¼ 0.674), with no
differences in procedural time, ﬂuoroscopy time, or
contrast volume used (Table 2). PCI complications
(such as coronary dissection, abrupt closure, no
reﬂow, coronary perforation, and catheter or stent
thrombosis) were also unrelated to route of access
in both female and male patients.
Compared with patients who had femoral access,
major vascular complications were reduced among
both women and men who had radial access, irre-
spective of whether PCI was performed (Table 3).
A signiﬁcant portion (86.1%) of the female patients
who had radial access noted that they would prefer
repeat radial access. Only 50.1% of patients who had
femoral access noted that they would prefer repeat
femoral access (p < 0.001).
Overall, the rates of major vascular complications
were higher in women than in men (4.7% vs. 1.7%;
p < 0.0001). Multivariable analyses were performed to
assess for possible predictors of major vascular com-
plications and radial-to-femoral access site crossover.
Signiﬁcant predictors of major vascular complications
included female sex (HR: 2.39; 95% CI: 1.76 to 3.25;
p < 0.0001), increase in age per 10 years (HR: 1.41; 95%
CI: 1.22 to 1.61; p < 0.0001), performance of PCI versus
no PCI (HR: 2.07; 95% CI: 1.41 to 3.04; p ¼ 0.0002), and
use of GP IIb/IIIa inhibitors (HR: 1.48; 95% CI: 1.07 to
TABLE 3 Comparison of PCI Versus No PCI in Women Undergoing Cardiac Catheterization Via Radial or Femoral Access
Radial PCI
(n ¼ 529, No PCI: n ¼ 379)
Femoral PCI
(n ¼ 577, No PCI: n ¼ 376) HR 95% CI p Value
Interaction
p Value
Primary outcome*
PCI 25 (4.7) 31 (5.3) 0.87 0.52–1.48 0.618
No PCI 11 (2.9) 17 (4.5) 0.63 0.29–1.34 0.228 0.478
Secondary outcomes: death, MI, or stroke
PCI 20 (3.7) 25 (4.3) 0.88 0.49–1.58 0.663
No PCI 9 (2.3) 13 (3.4) 0.68 0.29–1.59 0.375 0.627
Non-CABG major bleeding
PCI 8 (1.5) 9 (1.5) 0.96 0.37–2.49 0.934
No PCI 2 (0.5) 6 (1.6) 0.33 0.07–1.65 0.178 0.262
All death
PCI 7 (1.3) 11 (1.9) 0.69 0.27–1.79 0.448
No PCI 5 (1.3) 6 (1.6) 0.85 0.26–2.81 0.793 0.798
Major vascular complications
PCI 29 (3.2) 47 (8.1) 0.52 0.32–0.87 0.011
No PCI 6 (1.5) 12 (3.1) 0.47 0.17–1.25 0.129 0.861
Values are n (%). *Primary efﬁcacy outcome: composite of death, MI, stroke, or non-CABG bleeding.
Abbreviations as in Tables 1 and 2.
FIGURE 3 Predicto
Signiﬁcant predictors
These include wome
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5102.03; p ¼ 0.0165) (Figure 3). Signiﬁcant predictors for
radial-to-femoral access site crossover (Figure 4)
included female sex (HR: 1.39; 95% CI: 1.04 to 1.85; p ¼
0.023), increase in age per 10 years (HR: 1.14; 95% CI:
1.03 to 1.26; p¼ 0.0068), and previous CABG (HR: 2.95;
95% CI: 1.93 to 4.50; p < 0.0001).
DISCUSSION
RIVAL is the largest randomized trial to compare
radial with femoral access for coronary angiography
and intervention in patients with acute coronaryrs of Major Vascular Complications
of major vascular complications as assessed by multivariable analysis.
n, older age (per 10 years), patients undergoing percutaneous
n (PCI), and the use of glycoprotein (GP) IIb/IIIa inhibitors.
rval.syndromes (4). In addition, the subgroup of women is
the largest cohort of women to undergo randomiza-
tion to either radial or femoral access for PCI. The key
ﬁndings of this analysis for women are: 1) improved
safety with radial access, with a signiﬁcant reduc-
tion in major vascular complications; 2) similar PCI
success rates; and 3) women are at greater overall
risk for major vascular complications.
Current observational data also suggest that
women are at greater risk of post-PCI bleeding and
that radial access may reduce this risk (5,6). However,
operators may be reluctant to use radial access in
women because of increased radial artery spasm,
smaller arteries, and greater tortuosity.
Overall, in the RIVAL trial, the rate of major
vascular complications in women was more than
double that of men. Radial compared with femoral
access reduced major vascular complications by one-
half in women. Due to the higher baseline risk of
women, the NNT to prevent 1 major vascular com-
plication with radial instead of femoral access was
33 in women versus 49 for men.
Women randomized to radial access were more
likely to cross over to femoral access than men. This is
likely related to smaller radial arteries and higher
rates of radial spasm. Technical skill and use of 5-F
catheters help to extend the beneﬁts of radial access
to women. Despite these challenges, radial access
still reduced major vascular complications compared
with femoral access in women.
In terms of patient preference for subsequent
procedures, both women and men would prefer
radial access. This is important because despite
PERSPECTIVES
Prior studies have suggested that women have higher rates of
vascular access complications compared with men. However,
radial access may be technically more challenging in women due
to smaller radial arteries and radial spasm. In this analysis of the
RIVAL trial, radial access reduced major vascular complications
compared with femoral access in both women and men. Women
were found to have a higher risk of vascular complications, and
so they particularly beneﬁt from radial access.
FIGURE 4 Predictors of Radial-to-Femoral Access Site Crossover
Signiﬁcant predictors of radial-to-femoral access site crossover as assessed by multivari-
able analysis. These include women, older age (per 10 years), and previous coronary artery
bypass grafting (CABG). CI ¼ conﬁdence interval.
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511smaller radial arteries and the potential for increased
discomfort related to spasm, women chose radial
access for subsequent procedures.
The only other trial to assess radial versus femoral
access is the recent SAFE-PCI for Women (Study of
Access site For Enhancement of PCI for Women) (7).
This trial embedded randomization into the National
Cardiovascular Research Infrastructure and random-
ized 1,787 women to radial or femoral access, with
691 undergoing PCI. Unfortunately, the trial was
terminated early due to lower than expected event
rates. In addition, there was no signiﬁcant difference
in the primary efﬁcacy endpoint of Bleeding Acad-
emy Research Consortium bleeding (type 2, 3, and 5)
or vascular complications requiring intervention in
the PCI subgroup (radial 1.20%; femoral 2.90%; odds
ratio: 0.4; 95% CI: 0.1 to 1.3; p ¼ 0.21) (9). However,
in the overall population (diagnostic and PCI), there
was a signiﬁcant reduction in primary outcome
(radial 0.60%; femoral 1.70%; odds ratio: 0.3; 95% CI:
0.1 to 0.9; p ¼ 0.03). A major difference between
the cohorts of the SAFE-PCI for Women study and
the RIVAL trial was that RIVAL focused on pa-
tients presenting with acute coronary syndromes
(including STEMI, non-STEMI, and unstable angina),
whereas SAFE-PCI focused on elective referrals for
angiography and PCI (excluding STEMI). Even so, the
ﬁndings of the RIVAL subgroup are consistent with
SAFE-PCI, suggesting that radial versus femoral ac-
cess is effective at reducing major vascular access
site complications. Furthermore, the RIVAL trial
suggested that the beneﬁt of radial access in pre-
venting vascular complications is present in both
diagnostic and PCI cases.
STUDY LIMITATIONS. The results of the RIVAL trial
are not applicable to operators with little or no radial
experience. It is possible that interventional cardiol-
ogists selected women with larger radial arteries to be
randomized in the RIVAL trial.
Even though women versus men was a pre-deﬁned
subgroup, the RIVAL trial randomization was not
powered to assess differences between sexes, and
randomization was not stratiﬁed by sex.
Female sex is a subgroup analysis and so should be
considered hypothesis generating. However, theresults of our subgroup are consistent with an inde-
pendent randomized trial performed in women.
CONCLUSIONS
Women undergoing coronary angiography and PCI
are at higher risk of vascular complications compared
with men. Radial access is an effective method to
reduce these vascular complications.
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